Incretins risk remains unclear


There are no conclusive data. A link between diabetes and the risk of pancreatitis has been demonstrated 1 but the underlying mechanisms remain unclear. 2

Incretin mimetics rely on the glucose-lowering properties of the incretin hormone glucagon-like peptide (GLP-1), which stimulates insulin and suppresses glucagon secretion. 3 Therapeutic approaches for enhancing incretin action include use of GLP-1 agonists (e.g. exenatide, liraglutide) and inhibitors of dipeptidyl peptidase-4 (DPP-4), which